View Older Stories
-
BofA Securities Upgrades Charles River Labs (CRL) to Buy
-
Morgan Stanley Assumes Charles River Labs (CRL) at Equalweight
-
Charles River Laboratories (CRL) on Watch: CDC to end all monkey research - Science.org
-
Charles River Laboratories SEC probe ends with no enforcement action
-
Charles River Labs (CRL) PT Lowered to $197 at TD Cowen
-
Baird Upgrades Charles River Labs (CRL) to Outperform
-
Charles River Laboratories (CRL) Tops Q3 EPS by 9c ; Offers Guidance
-
Charles River Labs plans divestitures, cost cuts following review
-
TD Cowen Reiterates Buy Rating on Charles River Labs (CRL), lifts PT
-
William Blair Upgrades Charles River Labs (CRL) to Outperform
-
Barclays Upgrades Charles River Labs (CRL) to Overweight
-
Jefferies Upgrades Charles River Labs (CRL) to Buy
-
Charles River Labs (CRL) PT Raised to $175 at BofA Securities
-
Charles River Laboratories (CRL) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY25 EPS Guidance
-
Charles River explores crowdfunding partnership with BioTech Social
-
CFRA Downgrades Charles River Labs (CRL) to Hold
-
Citi Upgrades Charles River Labs (CRL) to Buy
-
Charles River Laboratories (CRL) and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research
-
Redburn-Atlantic Upgrades Charles River Labs (CRL) to Buy
-
Charles River Labs (CRL) PT Raised to $180 at Deutsche Bank
-
Evercore ISI Upgrades Charles River Labs (CRL) to Outperform
-
Charles River to initiate a review amid Elliott stake - Is a sale next?
-
Charles River Laboratories (CRL) Tops Q1 EPS by 25c; raises guidance
-
Charles River Laboratories (CRL) Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
-
Charles River Laboratories (CRL) on watch on chatter
-
Charles River Laboratories (CRL) options active into FDA reducing animal testing
-
Goldman Sachs Downgrades Charles River Labs (CRL) to Neutral
-
Jefferies Reiterates Hold Rating on Charles River Labs (CRL)
-
Citi Upgrades Charles River Labs (CRL) to Neutral
-
Redburn-Atlantic Upgrades Charles River Labs (CRL) to Neutral
-
Charles River Laboratories (CRL) Announces Agreement with Singapore General Hospital
-
Charles River Labs (CRL) PT Lowered to $175 at Evercore ISI
-
Charles River Laboratories (CRL) Tops Q4 EPS by 12c ; Offers Guidance
-
William Blair Downgrades Charles River Labs (CRL) to Market Perform
-
Charles River Labs (CRL) PT Lowered to $182 at TD Cowen
-
UBS Downgrades Charles River Labs (CRL) to Neutral
-
Charles River Labs (CRL) PT Lowered to $169 at Jefferies
-
Citi Reiterates Sell Rating on Charles River Labs (CRL)
-
JPMorgan Reiterates Neutral Rating on Charles River Labs (CRL)
-
TD Cowen Reiterates Hold Rating on Charles River Labs (CRL)
-
BofA Securities Reiterates Neutral Rating on Charles River Labs (CRL)
-
Charles River Laboratories (CRL) expects 2025 revenue will decline organically in a similar range as estimated in 2024
-
Charles River Labs (CRL) PT Lowered to $197 at Baird
-
Charles River Labs (CRL) PT Raised to $227 at TD Cowen
-
Charles River Labs (CRL) PT Raised to $211 at Baird
-
Charles River Laboratories (CRL) Tops Q3 EPS by 17c, provides guidance
-
Redburn-Atlantic Starts Charles River Labs (CRL) at Sell
-
Evercore ISI Downgrades Charles River Labs (CRL) to In Line
-
Citi Downgrades Charles River Labs (CRL) to Sell
-
Charles River Laboratories (CRL) and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research

